| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate |
2000-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f296c786f3e609964e3283ec3fabe3ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72339c6f1dfa3e1a2dc0bcecab0ea198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049808631efc7ef0e5851528f9885f06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf0a8b1bf4180e20c4880516bb3aa752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_853a8baf490c0473bdf9cc92d70abfb8 |
| publicationDate |
2000-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2000256191-A |
| titleOfInvention |
HMG-CoA reductase inhibitor dihydroxy open acids and salts thereof |
| abstract |
PROBLEM TO BE SOLVED: To provide a method and a pharmaceutical composition for inhibiting HMG-CoA reductase, and for treating and / or reducing the risk of diseases and conditions affected by inhibition of HMG-CoA reductase. Offer things. SOLUTION: The compound is formulated as a delayed release dosage form containing a therapeutically effective amount of a compound selected from statins dihydroxy open acid and pharmaceutically acceptable salts or esters thereof together with a pharmaceutically acceptable carrier. An oral pharmaceutical composition, wherein sufficient release of the compound from the dosage form is delayed until after the dosage form has passed through the stomach. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011153126-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007510714-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4839221-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007509990-A |
| priorityDate |
1999-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |